Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.55 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.54 |
| ▸ | MET | P08581 | 1/20 | 0.54 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.54 |
| ▸ | ROS1 | P08922 | 1/20 | 0.54 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.53 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.52 |
| ▸ | INSR | P06213 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1707236 | 1.00 | EGFR (0.55) | EGFRLRRK2METALKROS1 | |
| SCHEMBL1708506 | 0.95 | EGFR (0.59) | EGFRLRRK2METALKROS1 | |
| SCHEMBL9912362 | 0.94 | EGFR (0.60) | EGFRLRRK2METALKROS1 | |
| SCHEMBL9911248 | 0.94 | ALK (0.61) | EGFRLRRK2METALKROS1 | |
| Hydrochloric Acid SCHEMBL1707157 | 0.93 | EGFR (0.59) | EGFRLRRK2METALKROS1 | |
| SCHEMBL9911249 | 0.91 | ROS1 (0.53) | EGFRLRRK2METALKROS1 | |
| SCHEMBL9912344 | 0.91 | ROS1 (0.53) | EGFRLRRK2METALKROS1 | |
| SCHEMBL1707362 | 0.90 | EGFR (0.50) | EGFRLRRK2METALKROS1 | |
| SCHEMBL1707303 | 0.90 | MAPK3 (0.56) | EGFRLRRK2METALKROS1 | |
| SCHEMBL9911250 | 0.90 | MAPK3 (0.56) | EGFRLRRK2METALKROS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142667-A1 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142667-A1 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | ZAP70, LCK, DPY30 | EGFR 3420/4885LRRK2 3072/4885MET 4788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.